Physician profile
Leah Scheider
NPI 1134957574
$14,641.00
in general payments reported to CMS, 2019-2025
21 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $615 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $1,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,702.61 |
| Food and Beverage | $1,938.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $12,873.15 | 2024-2025 | Omnipod, Omnipod |
| Tandem Diabetes Care, INC. | $317.06 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $305.57 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $151.84 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novo Nordisk INC | $128.98 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $110.52 | 2024-2025 | Evenity, Repatha, Prolia |
| Medtronic, INC. | $90.49 | 2024-2025 | Minimed 780g |
| Cequr Corporation | $88.22 | 2025 | Cequr Simplicity |
| Beta Bionics, INC. | $87.02 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Mannkind Corporation | $77.79 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.60 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $66.77 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Amneal Pharmaceuticals LLC | $45.84 | 2024-2025 | Unithroid |
| Neurocrine Biosciences, INC. | $44.67 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $40.50 | 2025 | Yorvipath |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.08 | 2024 | Jardiance, Tradjenta |
| Antares Pharma, INC. | $35.78 | 2025 | Xyosted |
| Sanofi-Aventis U.S. LLC | $19.76 | 2025 | |
| Verity Pharmaceuticals INC. | $17.09 | 2025 | Tlando |
| Chiesi USA, INC. | $16.67 | 2024 | Mycapssa |
| Azurity Pharmaceuticals, INC. | $15.60 | 2025 | Azmiro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Scheider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.